• Chronic Pain
  • Contact
  • Depression
  • Home
  • Privacy Policy
  • PTSD
  • Terms and Conditions
  • Video
Wednesday, March 29, 2023
  • Login
ketamine.news
Advertisement
  • Home
  • Depression
    ketamine news

    Bronner’s Magic Soaps Becomes The First Company to Offer Ketamine-Assisted Therapy as Part of Employees’ Health Benefits

    ketamine news

    Popular Soap Company–Dr. Bronner’s– Plans To Explore The Psychedelic Space

    ketamine news

    Psychedelic and Plant Medicine Decriminalization Efforts Spread to the Midwest.

    ketamine news

    What There is to Know About Ketamine vs. Electroconvulsive Therapy (ECT)

    ketamine news

    Dispelling the Stigmas, Ketamine, and the Future of Mental Healthcare

    ketamine news

    A First of its Kind: Wellbeing Digital Sciences Delivers its “First Ketamine Treatment Under the Inpatient KITE Program”

    ketamine news

    Aggregate Study on the Efficacy of Ketamine to Treat Depression Shows Promising Results.

    Flow Integrative - Christi Myers

    Provider Spotlight – Christi Myers, Flow Integrative

    How To Help A Depressed Person

    How To Help A Depressed Person

  • Chronic Pain
    ER Doctor Aims for Patient Centered Breakthrough: A Ketamine That Works Orally

    ER Doctor Aims for Patient Centered Breakthrough: A Ketamine That Works Orally

    Ketamine: A Paradigm Shift in Pain Management

    Ketamine: A Paradigm Shift in Pain Management

    ketamine treatment for depression

    Amidst An Opioid Crisis, Ketamine Has the Potential To Save Lives

    Ketamine for pain

    Multi-Day Low Dose Ketamine Infusion For The Treatment Of Complex Regional Pain Syndrome

    ketamine for chronic pain

    End Chronic Back Pain with Ketamine for a Fuller Life

    ketamine for pain

    What You Should Know About Rheumatoid Arthritis

    ketamine for pain

    Myofascial Pain Syndrome: Symptoms, Causes, and Treatment

    ketamine for pain

    A sweet reprieve: Ketamine helps to relive phantom limb pain

  • PTSD
    ketamine news

    Dispelling the Stigmas, Ketamine, and the Future of Mental Healthcare

    ketamine news

    A First of its Kind: Wellbeing Digital Sciences Delivers its “First Ketamine Treatment Under the Inpatient KITE Program”

    veterans day

    Veterans’ Day: What Does PTSD Look Like In Veterans?

    PTSD awareness month

    PTSD Awareness Month: What Can I Do To Help?

    Trump Orders ‘a lot’ of Ketamine for Depressed Veterans

    Will Ketamine Be A Breakthrough Drug for PTSD?

    Ketamine to treat ptsd

    PTSD Sufferers ‘Healed’ With New Ketamine Infusion Therapy?

    ketamine to treat PTSD

    VA Uses Ketamine To Treat PTSD Effectively

    ketamine to treat ptsd

    Ketamine can help treat PTSD

  • Video
  • Ketamine Directory
  • Ketamine Media
  • Contact
No Result
View All Result
  • Home
  • Depression
    ketamine news

    Bronner’s Magic Soaps Becomes The First Company to Offer Ketamine-Assisted Therapy as Part of Employees’ Health Benefits

    ketamine news

    Popular Soap Company–Dr. Bronner’s– Plans To Explore The Psychedelic Space

    ketamine news

    Psychedelic and Plant Medicine Decriminalization Efforts Spread to the Midwest.

    ketamine news

    What There is to Know About Ketamine vs. Electroconvulsive Therapy (ECT)

    ketamine news

    Dispelling the Stigmas, Ketamine, and the Future of Mental Healthcare

    ketamine news

    A First of its Kind: Wellbeing Digital Sciences Delivers its “First Ketamine Treatment Under the Inpatient KITE Program”

    ketamine news

    Aggregate Study on the Efficacy of Ketamine to Treat Depression Shows Promising Results.

    Flow Integrative - Christi Myers

    Provider Spotlight – Christi Myers, Flow Integrative

    How To Help A Depressed Person

    How To Help A Depressed Person

  • Chronic Pain
    ER Doctor Aims for Patient Centered Breakthrough: A Ketamine That Works Orally

    ER Doctor Aims for Patient Centered Breakthrough: A Ketamine That Works Orally

    Ketamine: A Paradigm Shift in Pain Management

    Ketamine: A Paradigm Shift in Pain Management

    ketamine treatment for depression

    Amidst An Opioid Crisis, Ketamine Has the Potential To Save Lives

    Ketamine for pain

    Multi-Day Low Dose Ketamine Infusion For The Treatment Of Complex Regional Pain Syndrome

    ketamine for chronic pain

    End Chronic Back Pain with Ketamine for a Fuller Life

    ketamine for pain

    What You Should Know About Rheumatoid Arthritis

    ketamine for pain

    Myofascial Pain Syndrome: Symptoms, Causes, and Treatment

    ketamine for pain

    A sweet reprieve: Ketamine helps to relive phantom limb pain

  • PTSD
    ketamine news

    Dispelling the Stigmas, Ketamine, and the Future of Mental Healthcare

    ketamine news

    A First of its Kind: Wellbeing Digital Sciences Delivers its “First Ketamine Treatment Under the Inpatient KITE Program”

    veterans day

    Veterans’ Day: What Does PTSD Look Like In Veterans?

    PTSD awareness month

    PTSD Awareness Month: What Can I Do To Help?

    Trump Orders ‘a lot’ of Ketamine for Depressed Veterans

    Will Ketamine Be A Breakthrough Drug for PTSD?

    Ketamine to treat ptsd

    PTSD Sufferers ‘Healed’ With New Ketamine Infusion Therapy?

    ketamine to treat PTSD

    VA Uses Ketamine To Treat PTSD Effectively

    ketamine to treat ptsd

    Ketamine can help treat PTSD

  • Video
  • Ketamine Directory
  • Ketamine Media
  • Contact
No Result
View All Result
ketamine.news
Home Esketamine

Opinion: The New Ketamine-Based Antidepressant Is a Rip-Off

Ketamine News by Ketamine News
May 26, 2019
in Esketamine, Featured, Ketamine in The News
0
0
SHARES
108
VIEWS
Share on FacebookShare on Twitter

In a popular and public move, the United States’ Federal Drug Administration recently approved intranasal esketamine, one of the components of the psychedelic ketamine, for treatment-resistant depression. The nasal spray costs nearly $900 per dose—or roughly $7,000 for the first month of treatment, and each treatment takes at least two hours in a clinic. (It has yet to be decided how much of the cost insurance plans will cover.)

Esketamine can be unwieldy to use and carries a number of significant potential side effects. Shockingly, it was no better than placebo in two of the three short-term Phase-III studies submitted to the FDA for approval.

But the biggest problem at hand is not the drug itself. It’s the fact that instead of representing a revolution in mental health treatment, as it has been touted to do, esketamine is not a breakthrough at all. It’s just a way for pharmaceutical company Johnson & Johnson to make a significant profit off gullible insurance companies and vulnerable patients.

Generic Ketamine Works

Generic ketamine is available for a fraction of the price of esketamine, has been shown to work—and work safely—in small-scale single-dose and multidose trials for treatment-resistant depression, can be administered in a variety of ways, and has already been used off-label for decades to treat thousands of patients with depression and suicidality.

It’s currently difficult, if not impossible, to provide generic ketamine treatment in public clinics, even to patients who need it, because there haven’t been any large-scale, randomized trials, both with and without psychotherapy. Without these trials, and resources, physicians can’t be reimbursed by insurance companies for ketamine treatment like they will be able to do with esketamine.

Ordinary ketamine is a racemic medication, meaning it is made up of two molecules that are mirror images of each other. Because ordinary ketamine is generic, Johnson & Johnson simply isolated one of the two molecules in regular ketamine so that it qualified as “new.” The reality is that we don’t know whether esketamine is more or less effective than regular ketamine because there have been no head-to-head trials between the two. Johnson & Johnson only tested esketamine against a placebo, likely because they feared esketamine might actually perform worse than the generic version.

As many critics have pointed out, this strategy has become the bread and butter of drug development in the United States today. Largely because of the influence of pharma on the FDA itself, our drug approval process rewards copycat variation of already-available drugs instead of truly innovative pharmaceutical design.

When Psychotherapy Is Missing

The trials for esketamine also reveal a larger issue in the field: they de-emphasized the importance of psychotherapy while focusing solely on its chemical effects. The most effective treatment strategy for treatment-resistant depression is intensive psychotherapy along with the use of medication, but the FDA esketamine trials didn’t include therapy at all.

Getting insurance companies to pay for psychotherapy is already difficult, and without it as part of the protocol, they will likely offer no reimbursement for patients interested in receiving a psychotherapy session after their esketamine dose in order to process the experience.

Our colleagues who offer ketamine-assisted psychotherapy say that this is a vital part of the process. One such session can require upwards of three hours of one-on-one treatment in order to prepare patients for the experience, take care of patients while they are under the influence of ketamine, and then integrate the effects afterwards. Ironically, insurance companies would save more money paying for generic ketamine-assisted psychotherapy rather than esketamine treatment alone, as the former is both cheaper than the latter and can lead to long-term remission of symptoms.

Alternatives

Private ketamine clinics currently do exist, but they have to fight the stigma of the drug, and sporadic cases of malpractice. Some private clinics do not properly screen patients prior to initiating treatment and often charge outrageous sums of money—one reason that both patients and medical systems have been hesitant to implement it more widely. Those clinics that are providing ketamine responsibly, however, offer a potentially lifesaving treatment for patients living with depression who have exhausted all other available options.

Although there are no quick fixes for the broken drug-development and approval process that led us to esketamine, it is possible to take concrete steps to address the most glaring problems. Insurance companies and the FDA ought to require head-to-head study designs of clinical trials to investigate generic and patented medications. Additionally, current research on medication-assisted psychotherapy with other psychedelic substances such as MDMA and psilocybincan serve as a model for future research that explores ketamine-assisted psychotherapy, instead of the drug alone.

While Johnson & Johnson rakes in the profits from esketamine, patients dealing with depression and trying to navigate our struggling mental health system will bear the cost. Fostering the development of mental health treatments that are novel, effective, and affordable will require a critical examination of the undue corporate interests that drive drug approval in American psychiatry today.

Dr. Michael D. Alpert is a psychiatrist and clinical faculty at Harvard Medical School. He is also a therapist with the MAPS Clinical Study of MDMA-Assisted Psychotherapy for PTSD.

Dr. J. Wesley Boyd, MD is a psychiatrist and associate professor at the Center for Bioethics at Harvard Medical School.

Dr. Marco A. Ramos is a psychiatry resident at Yale University.

Previous Post

FDA-Approved Ketamine Nasal Spray Cuts Depression Symptoms in 24 Hours

Next Post

A sweet reprieve: Ketamine helps to relive phantom limb pain

Next Post
ketamine for pain

A sweet reprieve: Ketamine helps to relive phantom limb pain

Browse by Category

  • A Day in the Life
  • Esketamine
  • Featured
  • Ketamine Dictionary
  • Ketamine for Anxiety
  • Ketamine for Depression
  • Ketamine for Pain
  • Ketamine for PTSD
  • Ketamine in The News
  • Ketamine Treatment
  • Mental Health
  • Psychedelic Medicine
  • Suicide Prevention
  • Uncategorized
ketamine news
Privacy Policy | Terms and Conditions

Categories

  • A Day in the Life
  • Esketamine
  • Featured
  • Ketamine Dictionary
  • Ketamine for Anxiety
  • Ketamine for Depression
  • Ketamine for Pain
  • Ketamine for PTSD
  • Ketamine in The News
  • Ketamine Treatment
  • Mental Health
  • Psychedelic Medicine
  • Suicide Prevention
  • Uncategorized

Recent Posts

  • Capturing the Ketamine Experience in Real Time: A First-of-its-Kind Academic Paper from Denovo Therapy
  • Connecticut Approves a Bill That Could Pave Way for the Use of Psychedelic Substances to Treat Mental Health Illnesses
  • A Group of D.C. Advocacy Groups Have Joined Hands to Push For Drug Policy Reform in the Nation’s Capital
  • ‘Magic Mushrooms’ Look Set to Follow in the Footsteps of Cannabis
  • Bronner’s Magic Soaps Becomes The First Company to Offer Ketamine-Assisted Therapy as Part of Employees’ Health Benefits
  • Chronic Pain
  • Contact
  • Depression
  • Home
  • Privacy Policy
  • PTSD
  • Terms and Conditions
  • Video

© 2023 Ketamine News

No Result
View All Result
  • Home
  • Depression
  • Chronic Pain
  • PTSD
  • Video
  • Ketamine Directory
  • Ketamine Media
  • Contact

© 2023 Ketamine News

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In